Celon Pharma Promising Phase 2 Data for PDE10A Inhibitor in Parkinson’s Dyskinesia
Celon Pharma announced positive Phase 2 clinical trial results for its oral, once-daily PDE10A inhibitor, CPL’36, for treating Levodopa-Induced...
Jon Napitupulu
Cingulate ADHD Drug Shows Promise in Phase 3 Trials
Cingulate Inc. released positive Phase 3 safety data for CTx-1301 (dexmethylphenidate), its once-daily ADHD treatment. The data, encompassing pediatric...
Tiziana Life Sciences Files IND Application with FDA for ALS Phase 2 Trial
Tiziana Life SciencesLife Sciences has submitted an Investigational New Drug (IND) application to the FDA for a phase 2...
Nuvectis Pharma: Combination Therapy Improves EGFR Inhibitor Efficacy
Nuvectis Pharma announced promising preclinical research demonstrating the synergistic effects of combining its drug candidate, NXP900, with osimertinib (Tagrisso®)...
Cybrexa Unveils Promising Preclinical Data on Tumor-Selective PDCs at ESMO 2025
Cybrexa Therapeutics presented preclinical data at the ESMO Targeted Anticancer Therapies Congress 2025, showcasing their alphalex™ peptide-drug conjugates (PDCs)....
Reunion Neuroscience Raises Post Pardum Depression at MMH Forum
Reunion Neuroscience is participating in the 2025 Maternal Mental Health (MMH) FORUM to discuss RE104, its lead product candidate...
Onward Medical Advances Parkinson’s Pipeline with DoD, MJFF Support
ONWARD Medical received two grants to support early clinical feasibility studies of its ONWARD ARC-IM System for Parkinson’s disease....
Adverum Launches Phase 3 Study of Ixo-Vec for Wet AMD
Adverum Biotechnologies has launched the ARTEMIS Phase 3 study, a pivotal trial evaluating the efficacy and safety of a...
Pliant Therapeutics Announces Update on Phase 2b/3 Idiopathic Pulmonary Fibrosis Trial
Pliant Therapeutics halted its Phase 2b BEACON-IPF trial of bexotegrast for idiopathic pulmonary fibrosis (IPF) due to an imbalance...
Celldex’s Cdx-622 Shows Promise in Preclinical Inflammatory Disease Study
Celldex Therapeutics announced positive preclinical data for CDX-622, a bispecific antibody targeting thymic stromal lymphopoietin (TSLP) and stem cell...